# Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

> **NCT03000660** · PHASE1 · TERMINATED · sponsor: **Tufts Medical Center** · enrollment: 3 (actual)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03000660
- **Lead sponsor:** Tufts Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2019-10
- **Final completion:** 2019-10-10
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** partial clinical hold per FDA
- **Last updated:** 2020-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03000660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03000660, "Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03000660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*